EAU 2020: Ultrasound in Prostate Cancer Imaging: Dead or Ready to Get Started?
July 19, 2020 — UroToday.com
As part of a plenary presentation at the 2020 European Association of Urology (EAU) Virtual Annual Meeting assessing “Modern Prostate Cancer Imaging in Daily Practice”, Dr. Christophe Mannaerts examined the role of ultrasound in prostate cancer imaging.
While transrectal ultrasound is widely used to guide prostate biopsy, traditional grayscale ultrasound is unreliable in prostate cancer diagnosis. However, there have been many newer approaches to ultrasound that have been introduced to improve both the sensitivity and specificity.
Contrast-enhanced ultrasound (CEUS), particularly when combined with contrast-ultrasound dispersion imaging (CUDI), can be used for prostate cancer diagnosis. Compared to systematic biopsy, MRI targeted biopsy and CUDI-targeted biopsy performed similarly with respect to the detection of clinically significant disease. However, the use of CUDI was associated with a lower positive predictive value, ie. more false-positive findings, due to benign prostatic hyperplasia (BPH) and prostatitis.
Author: Christopher J.D. Wallis, MD, PhD – Urologic Oncology Fellow, Vanderbilt University Medical Center
Presented by: Christophe Mannaerts, MD – Department of Urology, Amsterdam University Medical Center, Amsterdam, Netherlands